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I. INTRODUCTION
Scientific knowledge and invention rapidly accelerated in the
past few decades, resulting in an untold number of broken barriers
and realized benefits. In 2001, scientists announced that the human
genome, consisting of 30,000 to 40,000 genes, had been fully
characterized.1  Arguably one of the most important scientific
breakthroughs in history, this accomplishment came far sooner than
anyone could have anticipated. 2 Fueled by the enormous marketing
potential in finding causes and cures for many diseases, the
1. See, e.g., Robert F. Service, High Speed Biologists Search for Gold in Proteins, 294
SCIENCE 2074, 2074 (2001); Lawrence M. Sung, The Unblazed Trail: Bioinformatics and the
Protection of Genetic Knowledge, 8 WASH. U. J.L. & POL'Y 261, 261-63 (2002) (discussing the
significance of the announcement that research teams had figured out the nucleotide sequence of
the human genome). The sequence was actually a "working draft" of the human genome, but the
project was expected to be completed in its'entirety in 2003. U.S. Dep't of Energy, Human
Genome Research, at http://www.science.doe.gov/ober/hug-top.html (last visited May 25, 2005).
2. See Sung, supra note 1, 261-263 & nn.2-3 (citing the complexity of the achievement and
the publicity it obtained).
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biotechnology industry invested heavily in the project with the hope of
maximizing control of genetic intellectual property and its potential
downstream value. 3
While the genomic revolution has steadily progressed, the
ability of researchers to identify and characterize proteins has
increased exponentially thanks to technological advancements. 4 The
culmination of the Human Genome Project only added to this
advancement and shifted the focus from genetic characterization to
the proteins they express. 5  The research effort to characterize
completely all proteins normally and abnormally expressed in the
human body is roughly known as proteomics. 6 Proteins hold vastly
more promise than even genes for drug discovery and medical
research, and proteomics has quickly "become the new darling of the
investment community."7 As with genomics, the biomedical industry
is rapidly attempting to claim as much patent territory in proteomics
as possible.8
Protein characterization is much more complex than gene
characterization, however, and proteomics projects are much less
certain to result in realized value.9 Further, proteomics patents raise
their own unique issues and are almost certain to clash with genomics
patents that may or may not cover the same claims. 10 Patent law
currently leaves those wishing to maximize their investment in
biological molecules uncertain of their ability to obtain sufficient
protection for their efforts. 1 Once decided, however, the resolution of
certain issues of patentability may give proteomics patent owners
3. See, e.g., Robert F. Service, Gene and Protein Patents Get Ready to Go, 294 SCIENCE,
2082, 2082 (2001) (discussing the race to patent genes thought to cause disease); Symposium,
Bioinformatics and Intellectual Property Law April 27, 2001 - Boston, Massachusetts: Molecules
vs. Information: Should Patents Protect Both?, 8 B.U. J. Sci. & TECH. L. 190, 202-07, 212-13
(2002) [hereinafter Molecules v. Information] (discussing biotech patenting in the pharmaceutical
industry); see also discussion infra Part II. (discussing downstream value).
4. See Service, supra note 1, at 2075 (citing use of rapid computerization and improvement
in techniques associated with protein identification, such as 2-D Gel Electrophoresis and X-ray
crystallography).
5. Id. at 2074-75.
6. Id.
7. Id. at 2074 (internal quotation marks omitted).
8. Id.; see also David Cyranoski, Intellectual Property: This Protein Belongs To.. ., 426
NATURE 10, 10 (2003) (reporting that Oxford GlycoSciences announced in 2001 that it expected
to patent over 4,000 proteins resulting from its disease research).
9. See, e.g., Cyranoski, supra note 8, at 10-11 (discussing the great costs associated with
patenting proteins which might deter experimentation if commercial value cannot be assured).
10. See, e.g., Service, supra note 3, at 2082-83 (citing the "confusing landscape of competing
gene and protein patent claims, perhaps setting the stage for legal battles for control over the
future of genetic medicine").
11. See infra Part III.
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more protection than is warranted under the traditionally accepted
patenting policy espoused in the Constitution of the United States. 12
Increased incentive for private industry also threatens the time-
honored research practices of scientific research, which supports the
open exchange of ideas and information throughout the scientific
community. 13
The future of biotechnology patents, therefore, is ripe for
litigation and may become a significant problem if not approached in a
distinctive manner. Due to the vast potential of discovery in
proteomics, its increasing industrial and academic value, and the
uncertainty of whether patent law will cover or allocate proper
incentives for these discoveries, adoption of patent protection may not
be the best approach to organize this field. Rather, some sort of sui
generis protection necessary to achieve the balance traditionally
envisioned by the patent laws.
Part II of this Note offers a brief overview of genomics,
proteomics, and the current state of biotechnology and information
technology in the field. This Part also provides a brief examination of
the requirements necessary to obtain a patent. Next, the Note
discusses current patent law as it applies to biotechnology and
genomic patents. The United States Patent and Trademark Office, as
well as the federal court system, has begun to recognize the
complexity and uniqueness of the field of biotechnology, but the lag
time between the development of technology and court decisions has
cast a large amount of uncertainty over the field. Part IV examines
the major problems and potential conflicts that may arise with this
nascent technology and the reasons why current patent law may never
be adequate for the proteomics industry. Finally, Part V argues that,
while other fields may have survived infancy under a general patent
law system, the proteomics field is better served by unique protection
that recognizes the special problems inherent in the field but
preserves the balance anticipated by the Constitution.
II. BACKGROUND OF PATENT LAW, BIOTECHNOLOGY, AND PROTEOMICS
The Constitution of the United States grants Congress the
power "[t]o promote the Progress of Science and useful Arts, by
securing for limited Times to Authors and Inventors the exclusive
Right to their respective Writings and Discoveries."'14  Congress
12. See infra Part IV.
13. See infra Part IV.B.
14. U.S. CONST. art. I, § 8, cl. 8.
[Vol. 58:3:955958
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responded by enacting the first Patent Act in 1790, which built upon
but changed in several important respects its English counterparts. 15
Since then, Congress has revised the Act many times to fit the
evolving interpretations of patent law and to respond to the many
changes in technology. 16
Congress and the courts have taken steps independent of the
Act itself to encourage technological innovation in the United States
by improving and stimulating the patent system. 17  A primary
example is Congress' formation of the Court of Appeals for the Federal
Circuit ("Federal Circuit") in 1982, which is responsible for
adjudicating all appeals that primarily involve patents.'8 Congress
hoped that a single appeals court would reduce uncertainty in patent
claim construction and increase the worth of obtaining a patent,
thereby promoting invention and disclosure of innovation. 19 Court
decisions have also stimulated the patent system by broadening the
traditional scope of patentable subject matter. In addition, the United
States Patent and Trademark Office ("USPTO") guidelines have
evolved in response to emerging issues and to judicial interpretations
of the Patent Act. 20 These judicial and administrative changes affect
the patentability of new and developing technology prevalent in the
biotech fields and impact the industry both positively and negatively.
15. See generally Edward C. Waltersheid, To Promote The Progress of Useful Arts: American
Patent Law and Adminstration, 1787-1836 (Part I), 79 J. PAT. & TRADEMARK OFF. SOC'Y 61, 71-
72 (1997) (discussing the inception and evolution of the Patent Act of 1790). Specifically, the Act
required an examination of the invention to determine if it was useful enough to be granted
protection, and a consideration of whether the invention was anticipated even outside the
borders of the country. Id.
16. Indeed, six Patent Acts were passed between 1793 and 1836 alone. Id. at 63. The latest
incarnation of the Patent Act was enacted in 1952. See Kathleen N. McKereghan, The
Nonobviousness of Inventions: In Search of a Functional Standard, 66 WASH. L. REV. 1061, 1062
(1991) ("The 1952 Patent Act enunciates the current requirements of patentability: utility,
novelty, and nonobviousness.").
17. See HERBERT F. SCHWARTZ, PATENT LAW AND PRACTICE 4-5 (3d ed. 2001) (noting the
"legislative and judicial action" in the 1980s taken in response to the "relative increase in
technological innovation throughout the rest of the world as compared with that in the United
States").
18. ROBERT P. MERGES ET AL., INTELLECTUAL PROPERTY IN THE NEW TECHNOLOGICAL AGE,
110-11 (3d ed. 2003). This jurisdiction includes patent related appeals from all U.S. District
Courts and appeals from the Board of Patent Appeals and United States Patent and Trademark
Office. 28 U.S.C. § 1295 (2003). Since patents are exclusively federal in origin, federal courts
have jurisdiction "exclusive of the courts of the states in patent," and there is no state patent
law. 28 U.S.C. § 1338(a) (2003).
19. See SCHWARTZ, supra note 17, at 4-5 (discussing the reasoning behind the 1982
establishment of the Court of Appeals for the Federal Circuit to hear all patent appeals).
20. Id. at 5.
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A. Genomics, Proteomics, and Bioinformatics: The Unique
Interrelationship Between Living Organisms and Technical
Information
To understand the impact patents have had and may have on
biotechnology in the future, it is necessary to describe briefly the
structure and function of genes and proteins and to explain exactly
what proteomics entails. Further, it is beneficial to understand the
importance of biological information collectively stored in public and
private databases and computer software processes that predict and
model proteins, methods together referred to as "bioinformatics," to
the further advancement of biotechnology. 21 All of these fields interact
with one another and will become further enmeshed in the future.
This makes application of traditional patent laws to biotechnology
increasingly problematic.
A genome is "an organism's complete set of DNA."22 DNA, or
deoxyribonucleic acid, is a biological molecule made up of building
blocks called "nucleotides" (named by the particular nitrogenous bases
they contain) that pair up distinctly to make two long chemical
chains. 23 "Sequencing" of a DNA molecule, therefore, is the complex
process of discovering the arrangement of the nucleotides in the
molecule and listing them in exact order. 24 The arrangement of the
nucleotides "spells out" the instructions that the particular DNA gives
to the living cell and makes up the genetic traits of an organism.25
Human DNA is arranged into 24 chromosomes, which range
from about 50 million to 250 million of the base pairs.26 Chromosomes
contain many different genes, which are "specific sequences of bases
21. See, e.g., Dov S. Greenbaum, The Database Debate: In Support of an Inequitable
Solution, 13 ALB. L.J. SCI. & TECH. 431, 445-48 (2003) (describing the rise of the importance of
database information to scientific discovery).
22. Human Genome Project, U.S. Dep't of Energy, From the Genome to the Proteome
[hereinafter Genome to Proteome], available at http://www.ornl.gov/sci/techresources/Human-
Genome/project/info.shtml (last visited May 25, 2005)
23. Id.; see also M. Scott McBride, Bioinformatics and Intellectual Property Protection, 17
BERKELEY TECH. L.J. 1331, 1335-36 (2002) (detailing the composition of DNA). The four bases
are adenine ("A"), guanine ("G"), cytosine ("C"), and thymine ("'"'). An A base will always pair up
with a T base, and a G base will always pair up with a C base. See, e.g., KATHLEEN TALARO AND
AUTHOR TALARO, FOUNDATIONS IN MICROBIOLOGY, 229-30 (1993) (detailing the makeup of DNA).
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that encode instructions on how to make proteins."27 Genes are only a
small part of the total genome; much of the DNA comprising
chromosomes serves other important functions in a living cell, such as
regulating protein production, and some genes may have unknown
functions or possibly no function at all.28
Genetic information flows from DNA to RNA (ribonucleic acid)
through a process called transcription.2 9 The information from the
genes contained in the RNA molecule is then deciphered by other
processes in the cell by a process called translation. 30 From these
processes, proteins are produced. 31  The publicly funded Human
Genome Project and its industry based competitors, therefore, have
sought to produce DNA sequence data for all of the chromosomes in
the human body and, from that information, have created a potential
road map to all of the proteins produced by human cells. 32
Deciphering proteins is a much more daunting task than
deciphering genes, however. Unlike DNA, which is made up of four
base pairs that only match up with one other pair, proteins are made
up of twenty different amino acids in a multitude of complex
combinations. 33 Proteins can range in size from 5,000 daltons 34 to over
a million Daltons; their electrical charges differ and can change based
on their bonding; and, in many cases, they exist either in very small
amounts in a cell or for only a miniscule amount of time.35 Since
many proteins are homologous,36 scientists typically categorize
proteins by general function in the cell.37 However, any change in
structure or binding of the protein may drastically alter its function
27. Id.
28. Id.




32. Service, supra note 3, at 2082-83.
33. TALARO, supra note 23, at 52-54, 230.
34. The unit for atomic mass, named after the prominent English chemist, John Dalton.
WEBSTER'S COLLEGIATE DICTIONARY 291 (10th ed. 1995).
35. Robert F. Service, Public Projects Gear Up to Chart the Protein Landscape, 302 SCIENCE
1316, 1317 (2003); Stanley Fields, Proteomics in Genomeland, 291 SCIENCE 1221, 1221 (2001).
36. Chemical compounds share the same homology if their physical structure differs only
very slightly, often by placement or character of only one carbon group. See, e.g., PHILLIPPE G.
DUCOR, PATENTING THE RECOMBINANT PRODUCTS OF BIOTECHNOLOGY AND OTHER MOLECULES
24-25 & n. 112 (1998) (discussing "structural similarity" of chemical compounds). This similarity
potentially can cause difficulty in protein patents failing for obviousness. Id.; see also discussion
infra Parts IIB, III.
37. C.f. Service, supra note 3, at 2083 (discussing the similarity in function of certain 'splice
variants'); Fields, supra note 35, at 1221-22 (discussing the characterization of proteins by
function).
9612005]
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and potentially cause the expression of disease. 38 Further, a single
gene may code for several different proteins through different
processes in a cell.39 In all, it is now estimated that up to two-million
distinct proteins are produced by human cells at some point in a given
person's lifetime. 40
The term "proteome" can be defined in several different ways
but is generally thought to be the "total set of proteins expressed
during the lifetime of a cell."'41 Proteomics encompasses the various
methods of obtaining the complete information about the proteins that
make up the proteome and involves all levels of analysis, such as
structural determinations of the proteins, functional analyses and, cell
modeling.42
While advances in technology have enabled protein researchers
to expand their focus and have greatly sped up the protein
characterization process, research is still time-consuming, and there
are no guarantees of profits or success. 43  Determination of the
structure of a protein alone involves deciphering four levels of
composition. 44 Determination of the function of a given protein is
much more difficult, since protein expression may change dramatically
with gene mutation, environmental disturbances or simple metabolic
fluctuations. 45 Because of the complexity currently inherent in the
field, it is estimated that protein structure determination may cost up
38. See, e.g., Service, supra note 1, at 2074 ("Defective proteins are responsible for the
chemistry that leads to a range of diseases from cancer to Alzheimer's.").
39. McBride, supra note 23, at 1336-37.
40. E.g., Service, supra note 1, at 2074.
41. Keala Chan & Dennis Fernandez, Patent Prosecutions in Proteomics, 19 SANTA CLARA
COMPUTER & HIGH TECH. L.J. 457, 461 (2003) (quoting P.C. TURNER, ET AL., INSTANT NOTES IN
MOLECULAR BIOLOGY (2d ed. 2000)). Proteomics, as the study of proteins on a massive scale, is
such a new field that the term was only coined in 1995. See, e.g., Michael Quinon, World Wide
Words, Proteomics, at http://www.worldwidewords.org/turnsofphrase/tp-pro3.htm (last visited
May 25, 2005).
42. Quinon, supra note 41.
43. For example, one technique, 2-D Gel electrophoresis, which separates proteins by both
weight and isoelectric point, has difficulty separating out key smaller weight and membrane
proteins, and requires much replication of experiments to reach a level of confidence with the
results. Service, supra note 1, at 2075-77; see also Service, supra note 35, at 1318 (discussing the
various research techniques used to discover the function of different proteins and the fact that
there is still "a long way to go" before the medical benefits of the research can be realized).
44. See, e.g., Chan & Fernandez, supra note 41, at 461-62 (explaining that these levels
include primary structure (chemical bonds and amino acid sequences), secondary structure
(typical formations), tertiary structure (the three dimensional folding patterns of the secondary
structures) and quarternary structure (organization of polypeptide chains)); see also TALARO,
supra note 23, at 52-54 (discussing the four structural layers of a protein).
45. Chan & Fernandez, supra note 41, at 461-62; see also Service, supra note 1, at 2074
(whereas genes "remain essentially unchanged through life, proteins are constantly changing,
depending on the tissues they are in, a person's age, and even what someone ate for breakfast.").
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to $100,000 dollars per protein with a discovery period that may
extend for years. 46
Nevertheless, the promises of finding proteins that directly
relate to major pharmaceutical breakthroughs, such as specific drug
targets, have fueled industry demand for extensive protein research.47
Several companies have merged or been created to rapidly
characterize bulk amounts of protein data or to sell the technology to
enable others to do so. 48 Other companies, even genomic-oriented
companies, are setting up labs to avoid being left behind by the
industry.49 Publicly funded projects, such as the Human Proteome
Organization ("HUPO"), also have been created as academic
researchers try to make sure they are not shut out of this scientific
avenue.
50
As with genomics in the 1990s, the race to identify proteins,
define their function, and patent them in the hope that immense value
may eventually be extracted from them may fuel proteomics research
at a heavier pace, especially in private industry.51 Determining who
should receive the downstream value of protein promises to be a viable
and contentious issue far into the future.52
46. Chan & Fernandez, supra note 41, at 462.
47. Service, supra note 1, at 2074 (discussing how the complexity and ubiquity of proteins is
what makes them more promising and attractive than gene research: "proteomics reveals the
nuts and bolts [of life]. . . . And blocking or boosting these proteins offers the straightest shot to
finding the next blockbuster drug."). The potential for medical benefits is enormous. See, e.g.,
Gynecological Cancer: Proteomics is the Newest, Most Promising Direction for Gynecologic
Cancer, CANCER WKLY., Jan. 6, 2004, available at 2004 V& 55262326 ("Proteomic technology is
the newest and most promising direction for translational developments in gynecologic cancers,
researchers report.").
48. See, e.g., Tim Adams, Celera, Inpharmatica Join For Drug Discovery, BIOTECHNOLOGY
NEWSWATCH, Nov. 19, 2001, at 2 (describing how Celera, a leading genomic company, has
integrated through cooperation with other companies to enter part of the proteomic market);
Sally Lehrman, Mergers, Acquisitions Seen as Fundamental to Growth, BIOTECHNOLOGY
NEWSWATCH, Feb. 4, 2002, at 1 (describing how Biotech companies look to expansion into
proteomic science and its technology through mergers).
49. See, e.g., Adams, supra note 48, at 1 (discussing how the pharmaceutical industry alone
has invested hundreds of millions of dollars in the first year after the complete draft of the
human genome was completed).
50. See Service, supra note 35, at 1316-18 ("HUPO helps set priorities, coordinate research,
set standards for handling and processing samples, and arrange for the use of common
bioinformatics tools to ensure that researchers can directly compare their results.").
51. See, e.g., Service, supra note 1, at 2075 ("The driving force is to crank through as many
proteins as possible to patent them."). Representatives of the pharmaceutical industry have
stated that patents in proteins, even if they have no present value, are obtained in mass
quantities because all other companies are doing the same thing and the company needs
property to trade. See Molecules vs. Information, supra note 3, at 212 ("[U]ltimately, someone is
going to hold a patent on every important drug target.").
52. In biomolecule patenting, downstream value may include all of the products derived
directly or indirectly from the protein, such as drugs which increase or decrease the level of the
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Further clouding the mix of patent law and biotechnology is the
burgeoning field of bioinformatics. Bioinformatics is "the research,
development, or application of computational tools and approaches for
expanding the use of biological... data."53  As genomics and
proteomics have generated volumes of information, bioinformatics has
grown to help decipher the data and generate predictions, statistics
and models to aid the process. 54 It has become a multi-million dollar
industry, and many of the tools and methods used in the field have
been patented. Private industry also has charged licensing fees for
the use of genome and proteome information, actions that some see as
contrary to the principles of science. 55
Although courts would probably hold abstract biological
information, such as the raw sequence data of proteins and DNA, to be
non-patentable, 56 biological molecules and bioinformatics pose unique
issues for patent law now and will continue to do so in the future. 57
Biological molecules are both compositions of matter and
informational molecules, and the patentability of the former may
prevent the use of the latter.58  Further, as computers and
biotechnology continue to form closer relationships, computers likely
will begin to use biological molecules as storage media.59  These
developments, which are beyond the scope of this Note, will stretch
protein in the system, or use the protein or byproduct to perform some other therapeutic
function. One of the problems with determining control of value-generating products is that the
genes that encode for the proteins are likely also patented, giving the owner, who may not be the
same as the protein patent owner, a viable claim to the products downstream of the gene, the
same "stream" as the protein. Molecules vs. Information, supra note 3, at 202-07.
53. McBride, supra note 23, at 1332 (quoting National Institutes of Health, Office of
Extramural Research, Bioinformatics at the NIH, available at http://grantsl.nih.gov/
grants/bistic/bistic.cfm (last visited May 5, 2002)).
54. See Charles Vorndran & Robert L. Florence, Bioinformatics: Patenting the Bridge
Between Information Technology and the Life Sciences, 42 IDEA 93, 93-95 (2002) (discussing how
bioinformatics can help manage biological information).
55. See infra Part III & n. 114; see also McBride, supra note 23, at 1332 n.7 (noting that
bioinformatics is expected to generate a worldwide revenue of over $2 billion in 2001 alone).
56. See McBride, supra note 23, at 1342 (explaining that the subject matter requirement of
patentability dictates that only a "process, machine, apparatus, or composition" may be patented
and thus suggesting that the abstract biological sequence may not be patentable subject matter).
57. See Vorndran & Florence, supra note 54, at 95 (noting that in 2000, the bioinformatics
industry raked in $700 million making it "one of the fastest growing areas of all life sciences
related markets").
58. See, e.g., Molecules vs. Information, supra note 3, at 199-202 (discussing the drawbacks
of patenting bioinformation).
59. See Vorndran & Florence, supra note 54, at 130 ("Bioinformatics inventions are unique,
however, because they combine the use of a computer and/or software with biological
information."). This enmeshing goes the opposite direction as well. Researchers have already
been successful in attempts to get a volume of DNA to solve a mathematical equation.
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patent law beyond its current limits and will warrant a new look at
the system in additions to the problems posed here.
B. General Requirements for Patenting an Invention
For the USPTO to approve an invention for patent protection,
the invention must meet several general requirements: (1) the subject
matter of the invention must be patentable; (2) the invention must be
useful, new and nonobvious; 60  (3) the patent specification must
disclose the invention such that another person in the field would be
able to make and use it; and (4) the invention must be distinctly
claimed, so others in the field will be able to ascertain the bounds of
the protection. 61 Obtaining a patent on an invention entitles the
owner to a presumption of validity in infringement actions and a
possible award of injunctive relief or monetary damages if a court
finds infringement has occurred.62
1. Statutory Subject Matter
According to the Patent Act, an invention may be eligible for
patenting if it is a "new and useful process, machine, manufacture, or
composition of matter."63  The Federal Circuit has stated that the
subject matter inquiry should focus upon whether the claim as a whole
is directed to that which is patentable, and that claims should not be
defeated simply because they contain elements that may not be
patentable. 64  This interpretation, along with other judicially
interpreted expansions, 65 has greatly lowered the threshold for
meeting the subject matter requirement. 66
60. Chan & Fernandez, supra note 41, at 449.
61. See Fiers v. Revel, 984 F.2d 1164, 1169-71 (Fed. Cir. 1993) ("We hold that when an
inventor is unable to envision the detailed chemical structure of the gene so as to distinguish it
from other materials, as well as a method for obtaining it, conception has not been achieved until
reduction to practice has occurred, i.e., until after the gene has been isolated.").
62. 35 U.S.C. §§ 282-284 (2003).
63. 35 U.S.C. § 101.
64. State St. Bank & Trust Co. v. Signature Fin. Group, 149 F.3d 1368, 1375 & n.10 (Fed.
Cir. 1998) (citing In re Shrader, 22 F.3d 290, 298 (Fed. Cir. 1994) (Newman, J., dissenting)).
65. See, e.g., Diamond v. Diehr, 450 U.S. 175, 192-93 (1981) (expanding recognition to
certain types of software that involve the use of a mathematical formula); Diamond v.
Chakrabarty, 447 U.S. 303, 317-18 (1980) (extending patentability to isolated microorganisms).
These cases are discussed in more detail infra Part III.
66. See infra Part III for further discussion of the Federal Circuit's approach to subject
matter qualifications and its impact on biotechnology patents.
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2. Utility
Similarly, there is an extremely low standard for usefulness
generally required for obtaining a patent. The invention must merely
be "capable of providing some identifiable benefit."67  The policy
behind this requirement is simple: an invention must show at the very
least that it works in order to be granted the patent monopoly.68 The
courts have expressed a reluctance to expand the requirement further,
fearing insertion of their own policy judgments on the function of a
particular patent. 69 There have been certain circumstances in which a
patent has been rejected for lack of utility,70 however, and it is more
likely to occur in groundbreaking technologies such as biotechnology. 71
Utility considerations, therefore, are paramount in the successful
crafting of a patent based on proteomics. 72
3. Novelty
The invention claimed in the patent application must also be
new: a single portion of an older reference ("prior art") must not
incorporate all of the claimed elements of the invention. 73 The novelty
requirement prevents a patent from issuing on an invention that was
known or used by others prior to the date of the invention or that was
disclosed in a publication in sufficient detail to enable someone to
understand and make the invention.74 This requirement exists simply
because it would be inequitable to reward someone a monopoly on an
67. Juicy Whip, Inc. v. Orange Bang, Inc., 185 F.3d 1364, 1365 (Fed. Cir. 1999) (overturning
the district court's ruling that the invention had lacked utility due to its deceptive nature and
imitation). "The fact that one product can be altered to make it look like another is in itself a
specific benefit sufficient to satisfy the statutory requirement of utility." Id. at 1367.
68. Merges, supra note 18, at 141-42.
69. Cf. id. at 141-45 (discussing the decline of the "moral utility" doctrine).
70. See, e.g., Brenner v. Manson, 383 U.S. 519, 523 (1966) (rejecting a process which
produced a steroid in which there was no known use, even though homologues of the structure
had a definite function).
71. See infra Part III. This occurrence is of particular concern in biotechnology considering
the wealth of information being generated by research which may or may not produce anything
sufficiently "useful," and also in light of the increased standards for utility in biotechnology
patents adopted by the USPTO. Utility Examination Guidelines, 66 Fed. Reg. 1092 (Jan. 5,
2001).
72. Lawrence M. Sung, IP Horizons in the Protection of Genetic Knowledge, AAPS
NEWSMAGAZINE, June 2001, at 20, 21-22.
73. Kalman v. Kimberly-Clark Corp., 713 F.2d 760, 772 (Fed. Cir. 1983). Novelty
requirements are described in 35 U.S.C. § 102 (a), (e) and (g). Schwartz, supra note 17, at 66.
74. 35 U.S.C. § 102(a) (2003). The requirement can at times be harsh. See In re Hall, 781
F.2d 897 (Fed. Cir. 1986) (denying an inventor a patent on his invention due to a single doctoral
dissertation publicly accessible in one library in Germany.).
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invention's use when another person had previously conceived of the
idea. 75
Statutory bars also preclude patentability of inventions that
were publicly used or sold by the inventor more than one year prior to
the filing of the patent application. 76 The date the invention was
created is generally considered the filing date, but in interference
actions, earlier dates may be established through evidence of
reduction to practice. 77 All of these requirements reward the diligence
of an inventor over his competitors.78 The hard-working inventor who
first conceives of the idea but takes longer to implement the concept or
file the application than a competitor is still able reap the benefit.7 9
4. Nonobviousness
The standard for showing that a claimed invention was not
obvious to those in the relevant community is more stringent than the
standards for usefulness and novelty.80  Congress wrote this
requirement into the 1952 Patent Act to codify a judicial requirement
of comparing the invention to its background skill of the art.81
Therefore, inventions not only have to be new, but also have to exhibit
some "inventive leap" beyond the background art.8 2 This requirement
is again in response to the policy that something "extra" must be
75. See Cherylyn A.P. Esoy, The PTO's 2001 Revised Utility Examination Guidelines For
Gene Patent Applications: Has the PTO Exceeded the Scope of Authority Delineated by the Court's
Interpretation of a "Useful" Invention?, 33 SETON HALL L. REV. 127, 139-140 (2002) (discussing
how § 102 ensures that patents are only awarded to inventors for only novel inventions); Merges,
supra note 18, at 147 ("Section 102 ... embodies the principle that only truly new inventions
deserve patents.").
76. 35 U.S.C. § 102(b).
77. 35 U.S.C. § 102(g). An interference action occurs when two inventors claim the same
patented invention. E.g., Schwartz, supra note 17, at 28-29.
78. See 35 U.S.C. § 102(g) ("In determining priority of invention under this subsection,
there shall be considered ... the reasonable diligence of one who was first to conceive and last to
reduce to practice, from a time prior to conception by the other.").
79. Merges, supra note 18, at 166-71. The "reasonable diligence" standard has been
interpreted as a balance between increasing the incentive to invent and the public interest in
"earliest possible disclosure," thus certain gaps in practice will cause the first inventor to lose the
right to the invention. Merges, supra note 18, at 168-69 (citing Griffith v. Kanamaru, 816 F.2d
624 (Fed. Cir. 1987)).
80. See 35 U.S.C. § 103(a) (2003) ( "A patent may not be obtained though the invention is
not identically disclosed or described as set forth in section 102. . ., if the differences ... are such
that the subject matter as a whole would have been obvious at the time the invention was made
to a person having ordinary skill in the art ... ").
81. Graham v. John Deere Co., 383 U.S. 1, 3 (1966).
82. Merges, supra note 18, at 183.
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shown in order for it to be equitable to others to grant the inventor
such strong protection.8 3
The nonobvious standard is particularly important in the
biotechnology field, considering that volumes of molecular information
generated in research cumulate in the public domain,8 4 and the many
parallels in structure and function of similar biological molecules.8 5
Further, scientific publications tend to speculate about the potential
ramifications of their research and the directions in which they foresee
the specific issue developing. The increase in publicly available
research information decreases the chances that several different
sources will not anticipate any given biotechnology invention.86
5. Written Description Requirements
Finally, for an invention to be patented, the application must
include a written description in its specification section "in such full,
clear, concise, and exact terms" that would enable someone skilled in
the art to create and use the invention, and it must disclose the "best
mode [of creation] contemplated" at the time the patent application is
filed.87 Disclosure of the invention itself is one of the essential parts of
the patent system-a quid pro quo for governmental protection-and
is expected to accomplish the goals set forth in the Constitution.88 The
description requirement also ensures that the inventor was in fact in
possession of the invention at the time the patent application was filed
and not merely attempting to patent a potential future innovation
before a competitor.8 9
83. Id.
84. For example, a National Institutes of Health project seeks to reduce the cost and time
spent in determining protein structures by grouping them into structural families in databases,
and anticipates up to 200 protein structures solved annually by 2005. Chan & Fernandez, supra
note 41, at 462-64. This is in addition to the mass of genetic and protein sequences already
publicly available in databases for many species, including humans. See, e.g., McBride, supra
note 23, at 1337-1340 & n.51 (2002) (citing one often used database, BLAST, which compares a
typed in biological sequence to known sequences in the database).
85. E.g., Merges, supra note 18, at 209-11.
86. Molecules vs. Information, supra note 3, at 215-216.
87. 35 U.S.C. § 112 (2003). The claims listed in the patent must also be distinct in
describing the subject matter that the patent covers, or be expressed in a "means or step for
performing a specified function" that covers the corresponding description and its equivalents.
Id.
88. See, e.g., Eldred v. Ashcroft, 537 U.S. 186, 216 (2003) (acknowledging the importance of
this exchange concept in patent law, but not in copyrights).
89. Enzo Biochem, Inc. v. Gen-Probe Inc., 296 F. 3d 1316, 1329 (Fed. Cir. 2002). See infra
Part III.A.-B. for further discussion of the importance of this requirement in biotechnology
applications.
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The written description requirement also serves to convey the
scope of the patent's protection to the public.90 Claim drafters attempt
to craft language broad enough to anticipate future developments of
the invention but not so broad as to be declared indefinite by the
courts or the USPTO. 91 Therefore, most patent litigation involves
disagreements between patent owners and potential infringers
concerning the interpretation of particular claims.92
III. THE STATE OF CURRENT PATENT LAW AND ITS APPLICATION TO
BIOTECHNOLOGY AND PROTEOMICS
A. The Interaction of Patent Law, Biology, and Biotechnology
Like many other technological and scientific fields,
biotechnology has progressed at a much faster rate than the prevailing
patent law. Patent law concepts have only very slowly incorporated or
adjusted to the biotechnology field. However, because of the economic
impact of the pharmaceutical industry and the vastly untapped
potential of biological research, more attempts are being made to
recognize the issues unique to biotechnology. These changes have
both positive and negative aspects on scientific research. Regardless,
the problems of proteomic research probably cannot be addressed
within the confines of the current system.
1. Early Biological Patent Issues
For much of the nation's history, the concept of patents
covering biological molecules such as DNA was foreign and contrary to
the principles of patent law and popular ethics.93 Any products of
nature were commonly thought to be unpatentable, and many argued
90. Schwartz, supra note 17, at 89.
91. See, e.g., Chan & Fernandez, supra note 41, at 468 (describing broad language used in
the patent for the drug Viagra).
92. As discussed infra, a major issue in patentability in the field of proteomics is the scope
of claims due to the time that is necessary to fully understand the potential functions of the
newly discovered protein. See also Chan & Fernandez, supra note 41, at 462-63, 468 ("Obtaining
FDA approval for a drug often takes substantially longer than patent prosecution, effectively
reducing the term of the patent once issued.").
93. See Molecules vs. Information, supra note 3, at 191-96 (discussing the development of
patenting DNA sequences); Diamond v. Chakrabarty, 447 U.S. 303, 318-320 (1980) (Brennan. J.,
dissenting) ("The Acts [do] not include living organisms."). Indeed, many people remain opposed
to this type of patenting, seeing it as treating life as a commodity. See, e.g., Human Genetics
Alert, The Human Genome Gold Rush, at http://www.hgalert.org/topics/lifePatents
/Patents2.html (last visited Oct. 15, 2005) (citing numerous arguments against gene patenting).
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that living things were beyond the scope of the written requirements
for patenting.94  Courts very early on recognized subject matter
products isolated and purified by man, such as proteins, as
patentable. 95 From this beginning has come a tendency to expand the
patentability of modified living matter. For example, Congress passed
the Plant Patent Act of 1930, which extended patent protection to
various asexually produced plants, and the 1970 Plant Variety
Protection Act, which extended patent protection to certain sexually
reproduced plants.96
The issue of whether living organisms could be patented
without the express approval of Congress came to the forefront in
Diamond v. Chakrabarty.97  The USPTO granted a patent to
Chakrabarty covering genetically altered bacteria specially designed
to break down the components of crude oil.98 The United States
fought this approval on several grounds, including the argument that
granting incentives to create genetically altered material would
possibly "spread pollution and disease, that it may result in a loss of
genetic diversity, and that its practice may depreciate the value of
human life."99 The Supreme Court, choosing a broad interpretation of
the Patent Act's subject matter requirements, held that Congress
intended to extend patent protection to "anything under the sun made
by man."100  Since the invention was man-made and not occurring
naturally in nature, it qualified for protection. 101
The Chakrabarty decision significantly altered the pace and
path of biotechnology development, since biotechnology researchers
were given another tool by which they could claim value for their
works. 10 2 In the years since the decision, patent procurement has
94. Chakrabarty, 447 U.S. at 311-12.
95. See, e.g., Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95, 103-04 (C.C.S.D.N.Y. 1911)
(accepting the patentability of purified adrenalin).
96. Chakrabarty, 447 U.S. at 310-11.
97. 447 U.S. at 303. The petitioner, representing the United States, argued unsuccessfully
that since bacteria were excluded from the 1970 Plant Act, Congress did not in general believe
that living things were patentable. Id. at 311.
98. Id. at 305-06.
99. Id. at 316.
100. Id. at 309. This broad interpretation of subject matter has been extended in subsequent
cases by the Federal Circuit. E.g., State St. Bank & Trust Co. v. Signature Fin. Group, 149 F.3d
1368, 1373 (Fed. Cir. 1998) (citing Chakrabarty, 447 U.S. at 309); AT&T Corp. v. Excel
Communications, Inc., 172 F.3d 1352, 1355 (Fed. Cir. 1999) (same).
101. Chakrabarty, 447 U.S. at 315-16.
102. See generally FOOD AND AGRICULTURAL ORGANIZATION, UNITED NATIONS, IPRs IN THE
FIELD OF BIOTECHNOLOGY FOR FOOD AND AGRICULTURE (discussing the path of biotechnology
development), available at http://www.fao.orgbiotech/C6doc.htm (last visited Feb. 25, 2005).
970 [Vol. 58:3:955
THE LIMITS OF PATENT LAW
been one of the major resources of biotechnology innovators. 10 3
Patents are used for their own value, for their leverage in licensing
negotiations, and for possible "reach through" to recoup on the
improvements of the patent's successors. 10 4 "Reach-through" licenses
are particularly contentious since they involve charging fees on the
sales of products developed through the patented technology but not
included in the claim and likely not foreseen by the patentee.10 5
2. The Human Genome Project and the Race to Patentable
Information
The United States Department of Energy ("DOE") and
National Institutes of Health ("NIH") founded the Human Genome
Project in the early 1990s for the purpose of coordinating a global
effort of sequencing the entire human genome and cataloging all of the
genes found in human chromosomes. 10 6 The project was supposed to
take well over a decade to complete. 10 7  However, advances in
technology, fueled partially by the fears that research corporations
would attempt to patent all of the sequence information they
generated, resulted in the project's early completion. 108
The experience of the genomics industry may be illustrative of
the positive and negative impacts that the possibility of patents will
cause as the focus of biotechnology shifts from the genome to the
proteome. The NIH originally set out to patent gene expressed
sequence tags ("ESTs") in its research but backed away from this
effort when it faced opposition from the USPTO and controversy in the
public. 10 9 At the time of this action, the majority of biotechnology
103. Patents in the molecules and the technology themselves are ubiquitous and offer
investments that are both attractive and legally dangerous to investors. See Donald R. Ware,
Research Tool Patents: Judicial Remedies, 30 AIPLA Q.J. 267, 269-70 (2002) (listing potential
research tool patents that an innovator may have to confront when searching for drug targets
with genomics or proteomics).
104. See generally Reid Adler, Corporate Strategies in the Genomics Industry, 3 YALE SYMP.
L. & TECH. 1 (2000) (providing "an overview of the various corporate patent strategies available
to genomics companies attempting to secure an influx of capital"). Indeed, there has been so
much of an increase in biotechnology patent applications that the USPTO has begun to craft
ways to limit their procurement. Esoy, supra note 75, at 128-30.
105.E.g., Ducor supra note 36, at 156-57; see also infra Part IV.
106. Human Genome Project, U.S. Dep't of Energy, About the Human Genome Project, at
http://www.ornl.gov/sciltechresources/Human-Genome/project/about.shtml (last visited May 25,
2005); see, e.g., Esoy, supra note 75, at 132.
107. Esoy, supra note 75, at 132.
108. Id.
109. Cyranoski, supra note 6, at 10. ESTs are fragments of DNA which of themselves may
have no function, but they can provide information about corresponding genes. See Human
Genome Project, U.S. Dep't of Energy, Genome Glossary, at http://www.ornl.gov/sci/techresources
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research was "not-for-profit," conducted in universities, and
established by unique funding. 110 Many feared that the "scientific and
medical advances promised by the human genome sequence would be
restricted by overarching patent claims.""'
However, members of the original research laboratories did not
give up on the possibility. As USPTO guidelines changed in the late
1990s, 112 corporations such as Celera began securing patents on these
types of biological information. Celera became the major competitor of
the Human Genome Project. 113 In 2000, Celera announced that it had
finished sequencing and applied for over 6,500 provisional patent
applications.1 4  Further, it planned to release the genomic
information it did not patent via a patented computer database
available to researchers only by subscription and attached to a non-
disclosure agreement.11 5 Other companies quickly followed suit."6
/HumanGenome/glossary/ (last visited May 25, 2005). Single nucleotide polymorphisms
("SNPs"), which are sequence variations occurring when a single base pair is altered, are another
form of biological matter which has proven contentious under patent law. Id.; see also, e.g.,
Sung, supra note 72, at 21.
110. Symposium, Bioinformatics and Intellectual Property Law April 27, 2001 - Boston,
Massachusetts: The Proper Scope of IP Rights in the Post-Genomics Era, 8 B.U. J. ScI. & TECH. L.
233, 242 (2002) [hereinafter Proper Scope].
111. Cyranoski, supra note 6, at 10. "A proliferation of intellectual property rights upstream
may be stifling life-saving innovations further downstream. . . ." Michael A. Heller and Rebecca
Eisenberg, Can Patents Deter Innovation? The Anti-commons in Biomedical Research, 280
SCIENCE 698, 698 (1988). This argument is further developed in infra Part Iv.
112. "In February 1997, the USPTO adopted a controversial position when it announced the
likely grant of patent claims to ESTs and SNPs, despite minimal disclosure of their biological
significance by the patent applicant." Sung, supra note 1, at 282. Since this time, the USPTO
has completely reversed its guidelines causing considerable confusion as to the validity of these
types of patents. See Esoy, supra note 74, at 153-54, 163-64 (arguing that the standards are
contrary to the relatively lax position adopted by the Federal Circuit).
113. See Celera, Our History [hereinafter Our History] (describing Celera milestones in
mapping the human genome), available at http://www.celera.com/celeralhistory (last visited Feb.
23, 2005).
114. Jennifer Doran, Celera Genomics to Complete DNA Map, 28 J. L. MED. & ETHICS 188,
188 (2000). Provisional patents give inventors a set time to determine if full patent protection is
justified. Id.; e.g., 35 U.S.C. § 111(b) (2003).
115. Our History, supra note 113; Amol Pachnanda, Comment, Scientific Databases Should
Be Protected Under a Sui Generis Regime, 51 BUFFALO L. REV. 219, 219-220 (2003); McBride,
supra note 23, at 1338.
116. For example, Genomics Solutions, Inc. and Affymetrix Corp., two of the leaders in
genomics and proteomics research, require use of their products system to access their rapidly
expanding databases of molecular information. See Genomics Solutions, Inc., Home (important
notices on sign-in), at http:/bioinformatics.genomicsolutions.com/index.html (last visited May 25,
2005); Affymetrix Corp, NETAFFX Analysis Center (same), at http://www.affymetrix.coml
analysis/index.affx (last visited Feb. 23, 2005). Of course, the expenses in developing systems
such as these may justify restricting access to certain information obtained in the research
process.
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Today, just two of the major genomics companies have filed over
25,000 DNA-based patent applications. 117
While Celera and other private industry giants justifiably seek
to maximize profits extracted from their labor, their actions are
threatening to the traditional, academically-oriented scientific
community, which has long operated on the proposition of freely
transferred information and data, peer review, and publication. 118
The race to patent resulted in a backlash that caused an influx of
publicly generated information designed to create prior art to defeat
patent claims. 119 Public scientific research has managed to survive
and compete with private industry in the field of biotechnology.
Recent developments in patent law interpretation, however, threaten
to shut out universities from anything but basic research in the field
and potentially may alter the dynamics of scientific research as a
whole. 120
B. The USPTO and the Federal Circuit's Patent Act Interpretations
and Their Implication on Proteomics Patents
Biotechnology patent applications are generally evaluated like
any other patent by both the courts and the USPTO. 121  This
evaluation can cause problems because the biotechnology field does
not lend itself to traditional patent law concepts. 22  Recently,
however, there has been some recognition of the unique aspects of
biotechnology reflected in both the USPTO's guidelines and the
Federal Circuit's interpretation of those guidelines. This equal
treatment of biotechnology with respect to some patent requirements
and special treatment with respect to others has and will continue to
117. These are Human Genome Sciences and Incyte Genomics. Service, supra note 3, at
2082.
118. Pachnanda, supra note 115, at 220. Indeed, peer review and publication of scientific
data are so pervasive that they have long been instrumental factors in whether expert scientific
testimony is admissible in courts. See, e.g., Daubert v. Merrell Dow Pharmaceuticals, Inc., 509
U.S. 579, 594 (1993) ("The fact of publication (or lack thereof) in a peer reviewed journal thus
will be a relevant, though not dispositive, consideration in assessing the scientific validity of a
particular technique or methodology on which an opinion is premised.").
119. Molecules vs. Information, supra note 3, at 201.
120. E.g., Cyranoski, supra note 6, at 10. For example, a company who owns a patent on a
gene and a patent for a target protein resulting from that gene may theoretically be able to claim
any process or product downstream from the protein as within their claim, resulting in total
control over a specific drug target and its homologs. See, e.g., Molecules vs. Information, supra
note 3, at 94 ("They patent what they can, and they hope that some of those patents will some
day help them make a profit, maybe by allowing them to capture a share of the profits on future
drugs."). This problem is discussed infra Part IV.
121. It is precisely this equal treatment that this Note argues against.
122. See supra discussion in Parts II., III.A.1.
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cause confusion and legal controversy. Of particular importance are
these institutions' interpretations of subject matter, the written
description requirement, the utility requirement, the scope of patent
claims, and, recently, the experimental use exception.
1. Further Extension of Subject Matter to Include Business Methods
and Software Directly Impacts Bioinformatics
Several Federal Circuit decisions have reinterpreted the scope
of a patent's subject matter and written description requirements.1 23
These sections of the patent statute appear to have been the "principal
sites in which the U.S. Federal Circuit's structural conception of
modern biotechnology has been reflected" 124 and where the most
change with respect to biotechnology in the patent law has occurred.
First, with respect to statutory subject matter, the Federal Circuit
rejected limitations on patentability of an invention, so long as it "falls
within at least one of the four enumerated categories" of section
101.125 The court abandoned several traditional "judicially-created"
exceptions to patentability and, instead, focused simply upon whether
the methods or processes claimed in the invention, as a whole, produce
"useful, concrete and tangible results" and whether they meet the
other requirements of the patent statute. 126 The decision opened the
way to increased acceptance of the patentability of software
applications. 127
In AT&T Corp. v. Excel Communs., Inc.,128 the Federal Circuit
reiterated its focus on the claim's usefulness in satisfying the broad
principles of section 101. Excel, defending an allegation that they
infringed on a software patent, contended that claims involving
mathematical algorithms as part of their function could only meet the
patentable subject matter requirements of section 101 if the process
123. See 35 U.S.C. § 101 (setting forth the subject matter requirements); 35 U.S.C. § 112
(setting forth the written description requirements).
124. Justine Pila, Bound Futures: Patent Law and Modern Biotechnology, 9 BU. J. SCI. &
TECH. L. 326, 345 n.57 (2003).
125. State St. Bank & Trust Co. v. Signature Fin. Group, 149 F.3d 1368, 1372 (Fed. Cir.
1998). The categories permissible for patenting are "any new and useful process, machine,
manufacture, or composition of matter." 35 U.S.C § 101 (2003).
126. State St. Bank, 149 F.3d at 1373-76. Specifically, the court rejected the "business
method" exception as it categorically distinguished between business and other processes, and
the "mathematical algorithm" exception, to the extent that it was used to exclude any kind of
invention making use of mathematical subject matter and not limiting its use to inventions that
represented abstract ideas standing alone. Id.
127. See Vorndran & Florence, supra note 54, at 108 ("The result... is that pure software
patents are here to stay .... ).
128. 172 F.3d 1352 (Fed. Cir. 1999).
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"physically transformed" the data it used into another form. 129 The
court stated that, while a claimed transformation of data sufficiently
satisfied section 101, it was not due to the transformation but rather
because a change in form demonstrated the production of a "useful,
concrete tangible result."130  Therefore, any claim that utilizes
unpatentable subject matter 131 to produce a useful result should at
least satisfy the low threshold of section 101 for patentability.
Decisions such as AT&T are profoundly important in the proteomics
field, since the use of biological databases for identifying and assessing
results is essential to the efficiency of the industry.1 32 Since databases
can now be patented and the information contained in them secured
by agreements not to disclose, another traditional publicly available
route to research data is now protected through the patent monopoly.
133
2. Relaxation of the Written Description Requirement
With its decision in Enzo Biochem, Inc., the Federal Circuit has
also responded to the unsettled nature of biotechnology by altering its
interpretation of the patent statute's written description
requirement.134 Just five years before the Enzo decision, the court
applied its traditional written description analysis to reject a claim for
human insulin cDNA based on the successful cloning at the University
of California of a similar sequence in rats.1 35 The court stated that, to
be adequate, a written description of a biological molecule "'requires aprecise definition, such as by structure, formula, chemical name, or
129. Id. at 1358-60.
130. Id. at 1358-59.
131. These include "laws of nature, natural phenomena, and abstract ideas." Diamond v.
Diehr, 450 U.S. 175, 185 (1981).
132. See generally Vondran & Florence, supra note 54 (discussing the role of bioinformatics
in the pharmaceutical industry for the efficient development of drugs based on proteins
discovered through proteomic techniques).
133. Further, scientists who wish to start genomic or proteomic research will have to license
from the company the database, the information contained in the database, and all of the
technology necessary to generate their own data in a total package. See, e.g., Genomic Solutions,
Proteomics (exhibiting their full range of researching tools and data integration), at
http://www.genomicsolutions.com/showPage.php?cachevar=&menulD=361 (last visited Feb. 23,
2005).
134. "The specification shall contain a written description of the invention.., in such, full,
clear, concise, and exact terms as to enable any person skilled in the art to which it pertains ...
to make and use the same .... 35 U.S.C. § 112 (2003).
135. See generally The Regents of the Univ. of Cal. v. Eli Lily & Co., 119 F.3d 1559, 1562-69
(Fed. Cir. 1997) ("[A] cDNA is not defined or described by the mere name 'cDNA' ... but requires a
kind of specificity usually achieved by means of the recitation of the sequence of nucleotides that
make up the cDNA.").
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physical properties,' not a mere wish or plan for obtaining the claimed
chemical invention."'13 6 Therefore, under Lilly, one has to know the
exact structure, not simply the functions of the molecule, in order to
patent a claim successfully. 137 The decision was steeply criticized as
heightening standards for the biological industry in comparison to
other fields.138
The Federal Circuit appeared to affirm this decision in Enzo
Biochem, Inc. v. Gen-Probe Inc.,139 when it affirmed that nucleic acid
probes, which were defined by biological activity and deposited
publicly, did not satisfy section 112 with respect to written
description. 40 Enzo received a patent for its invention of molecular
probes that reacted exclusively with the DNA of the bacteria that
cause gonorrhea.' 4 ' To meet the written specification requirements of
the Patent Act, it deposited a sample of the actual recombinant DNA
molecule at the American Type Culture Collection ("ATCC"). 142 The
court stated that describing a molecule by its function and sequence
"fails to distinguish it from other molecules that can perform the same
function."'143 The written description requirement must not only enable
one skilled in the art to "make and use" the invention but must also
show with "reasonable clarity to those skilled in the art that, as of the
filing date sought, he or she was in possession of the invention."'144
On rehearing, the court vacated and reversed the judgment 45
and signaled that it may be more tolerant of the unique and uncertain
qualities possessed by biological inventions. 46 The court, adopting the
136. Id. at 1566 (quoting Fiers v. Revel, 984 F2d 1164, 1171 (Fed. Cir. 1993)).
137. Id. at 1568. A description of one type of mammalian DNA is not a description of the
genus. Id; see also John C. Stolpa, Toward Aligning the Law With Biology? The Federal Circuit's
About Face in Enzo Biochem, Inc. v. Gen-Probe, Inc., 4 MINN. INTELL. PROP. REV. 339, 350 (2003)
(discussing the ramifications of Eli Lilly on those pursuing patents in DNA technology).
138. Stolpa, supra note 137, at 350-351.
139. 285 F.3d 1013, 1020 (Fed. Cir. 2002).
140. See id. at 1018-20 ("We also conclude that Enzo's claims do not meet the written
description requirement.. [and] § 12, 1 is not met.").
141. Id at 1015-16.
142. Id. at 1016. The ATCC is a non-profit organization that collects, preserves and
distributes biological materials and information to industry and academia for the purposes of
furthering research. It has grown to be one of the world's largest warehouses of biological
materials. See ATCC, The Global Bioresource Center, About ATCC, at http://www.atcc.org/
About/AboutATCC.cfm (last visited Feb. 25, 2005) (providing an overview of the organization).
143. Enzo, 285 F.3d at 1019.
144. Id. at 1020 (quoting Vas-Cath Inc. v. Mahurkar, 935 F.2d 1555, 1563 (Fed. Cir. 1991)).
145. Enzo Biochem, Inc. v. Gen-Probe Inc., 296 F. 3d 1316, 1320 (Fed. Cir. 2002).
146. The court's reasoning was based "[iun light of the history of biological deposits for
patent purposes, the goals of the patent law, and the practical difficulties of describing unique
biological materials in a written description." Id. at 1325; see also Stolpa, supra note 137, at 357
(stating that the decision appears to be a "concession" to biologists).
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guidelines used by the USPTO, refused to accept that all biological
material described in functional terms fell short of the written
requirements if the claim incorporated a "disclosed correlation" with a
"sufficiently known" structure. 147 Therefore, since "words alone" are
often not satisfactorily enabling or demonstrative of possession of the
invention claimed, the court was willing to accept that a deposit of
claimed material in a publicly accessible depository and incorporation
by reference in the specification adequately described the claim for
purposes of section 112.148 This broadening of statutory interpretation
represents an alternative method by which biological researchers may
be granted protection without expending valuable time and money
racing for the exact sequence or structure of the molecule they have
isolated or cloned. 149 The court also believed that a materials deposit
properly referenced in the invention's specifications represented an
adequate exchange of information for the patent monopoly. 150
The decision in Enzo has important ramifications to the
proteomics field. As previously stated, proteins are likely to be
discovered and isolated initially by structure and afterwards by
function, and an exact written description alone may not have been
enough to satisfy the requirements of section 112.151 Further, even if
a structural or chemical description of the invention may be adequate,
the level of disclosure of the invention is of crucial importance. 152 It is
only much later in the research and development of isolated proteins
that their complete functionality can be comprehensively
understood. 15 3 An inventor may be left with patent protection for a
particular protein function that has no value after the disclosure of
the information results in a multitude of different applications
impossible to anticipate at the time of the initial discovery. 154
While Enzo potentially has broadened the scope of biological
patent protection, it has left many questions unanswered and has
been the subject of criticism due to the uncertainty it has generated in
147. Enzo, 296 F.3d at 1324-25. The PTO guidelines are discussed in greater detail, infra
Part III.
148. Id. at 1325-26 (quoting MPEP § 2402 (8th ed. Aug. 2001). This assumes that all other
requirements for patentability are also satisfied. Id.
149. See Stolpa, supra note 137, at 357 ("Enzo II purports to provide additional means by
which inventors might also meet [the written description requirement].").
150. Enzo, 296 F.3d at 1330.
151. Chan & Fernandez, supra note 41, at 461-62.
152. Id. at 468.
153. Id. at 462.
154. See, e.g., Molecules vs. Information, supra note 3, at 205-06 (arguing that drugs




claim crafting.155 The decision does not render all functional
descriptions, or even all deposits of biological material, adequate for
section 112 requirements. 156 While a broadened written description
possibly may allow a researcher to claim more within his limited area
of innovation, such as downstream products or unforeseen functions,
inventors may still be confined to the sequence that must be
disclosed.1 57 Simply "establishing goals does not a patent make," 158
and courts remain adamant that there must be enough referencing or
description to enable others skilled in the art to recognize possession
of the invention and to reproduce it.159  Some analysts believe,
therefore, that Enzo still does not allow for a biological innovation to
"reach through" to subsequent, but initially unrecognizable, uses. 160
3. Utility - USPTO and the Federal Circuit Currently Have Different
Standards for Biotechnology
As stated previously,16' the Federal Circuit has developed a
very relaxed standard in considering utility. However, the USPTO
recently has adopted specific guidelines addressing the requirement of
utility with respect to gene patent applications. 162 This occurred in
response to the controversy engendered from relaxing the guidelines
to allow the patentability of EST fragments and SNPs.163 The
previous guidelines were designed to "give proper deference" to
biotechnologists and required only that an invention show "specific"
and "credible" utility.' 64 The relaxed guidelines had allowed EST
155. See generally Harold C. Wegner, When a Written Description is Not a "Written
Description" When Enzo Says it's Not, 12 FED. CIR. B.J. 271 (2002) (attacking the decision on
several grounds).
156. See, e.g., Stolpa, supra note 137, at 358-62 ('Making a biological deposit may now be
used to demonstrate possession, but this is contingent on the accession number of the deposit
being recited in the specification."); see also Univ. of Rochester v. G.D. Searle & Co., 249 F. Supp.
2d 216, 219-235 (W.D.N.Y. 2003) (holding that a claim for two related human enzymes that could
potentially be used to produce a stomach pain reliever did not meet § 112 because, while
providing a function for the enzymes, the claim did not disclose the organic compounds necessary
to provide that function).
157. Stolpa, supra note 137, at 360; Merges, supra note 18, at 139-41.
158. Univ. of Rochester, 249 F. Supp. 2d at 218.
159. Id.
160. See generally John R. Thomas, Formalism at the Federal Circuit, 52 AM. U. L. REV. 771,
800-01 (2003) (discussing the relative flexibility of claim constructions in biotechnology versus
other scientific industries). "Reach-through" licenses are defined supra in Part H.A.
161. See supra Part II.B.
162. Utility Examination Guidelines, 66 Fed. Reg. 1092 (Jan. 5, 2001).
163. See supra note 111 and accompanying text.
164. Esoy, supra note 75, at 150-51 (discussing Utility Examination Guidelines, 60 Fed. Reg.
36323 (July 14, 1995)).
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patents to be approved without failing for lack of utility during the
late 1990s. 165
The new utility guidelines establish that biotechnological
patents must possess a "specific, substantial and credible" utility in
order to be patentable. 166 The specificity requirement ties the utility
to the subject matter claimed. 167 This means that gene fragments
would have to be able to state a specific function or connection that
corresponded to the claimed nucleic acid. 168 Further, the "substantial"
language may be interpreted as requiring a "real world use," rather
than simply the ability to predict or identify other biological molecules
and data.1 69
Strengthening the utility requirement for biotechnology
inventions may be a step in the right direction towards the recognition
of the unique problems in the field.1 70 The prevention of broad-
reaching biotechnology patent claims at least demands that more
functional research be conducted before intellectual property territory
can be claimed. 17' However, the new rules are in direct opposition to
the Federal Circuit's broad interpretation of the utility requirement
and may meet with some consternation if challenged in court.1 72 The
Federal Circuit repeatedly has held the statutory requirement of
utility is met if "it is capable of providing some identifiable benefit."'173
The Federal Circuit is not bound by the USPTO policy determinations
and only uses them as a guide to its interpretation of the law. 74
Therefore, the court may, and at least one paper has argued it should,
decide that the policy is too restrictive under the language of the
statute.175 Either way, Congress arguably is in a better position to
address the issue.
165. See Esoy, supra note 75, at 150 (citing, for example, U.S. Patent No. 5, 817, 479 issued
to Incyte, Inc. with the EST's stated utility of being able to "generate kinase homologs").
166. Id. at 152.
167. Id.
168. Claimed nucleic acid structure, which can easily be obtained from these fragments, are
unpatentable without a claimed utility for the gene they disclose. Sung, supra note 1, at 283 &
n. 121.
169. Esoy, supra note 75, at 153.
170. The new guidelines were met with general approval in the scientific community. Id. at
152.
171. Chan & Fernandez, supra note 18, at 469-70.
172. Id.
173. Juicy Whip, Inc. v. Orange Bang, Inc., 185 F.3d 1364, 1366 (Fed. Cir. 1999).
174. See, e.g., Esoy supra note 75, at 156 ("It is clear that the PTO does not have unfettered
discretion on these matters.") (citing Enzo Biochem, Inc. v. Gen-Probe, Inc., 296 F.3d 1316, 1324
(Fed. Cir. 2002)).
175. See id. at 157-65 ("By judging patent applications against the 'specific, substantial, and
credible' utility standard, the PTO is effectively denying patents to inventions that should
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4. Claim Breadth: Interpretations Lead To Patenting Uncertainty
Industry and individual researchers who wish to obtain any
profit from biological molecule patents must try to craft them as
broadly as possible. 176 Navigating the fine line between claims that
are too broad to be accepted and too narrow to produce value is not
unique to biotechnology patents. 177  This tension, however, is of
particular importance in the patenting of biological molecules because
of the existence of a multitude of structurally and potentially
functionally equivalent molecules that may not be discovered until
after the patent is issued. 178 A functionally equivalent protein, for
example, that was adjudged not to be covered by the patent would
completely undercut the patent's value. 79 For this reason, much of
the patent prosecution process involves the fine-tuning of claims. 80
The judicially created doctrine of equivalents has allowed
patentees to stake claim to certain "insubstantial variations" that are
beyond the literal bounds of the claim.' 8 ' However, the Supreme Court
recently stated that an applicant who surrenders subject matter
during the prosecution process due to the USPTO's rejection of the
patent's specification is estopped from reclaiming the same subject
matter under the doctrine of equivalents. 8 2 The decision has led
prospective patentees to fear that protein patents would have to
"meticulously and individually disclose and claim each and every
functionally equivalent homolog" in order to protect the value of the
receive patent protection"). Another potential argument, however, with respect to protein
patents and utility is that, despite the Federal Circuit's relaxation of the standards for other
patents, proteins must meet the substantial utility standard of Brenner. See Brenner v. Manson,
383 U.S. 519 (1966) ('The basic quid pro quo contemplated by the Constitution and the Congress
for granting a patent monopoly is the benefit derived by the public from an invention with
substantial utility.").
176. Merges, supra note 18, at 144-149.
177. See, e.g., Jacob S. Wharton, Festo and the Complete Bar: What's Left of the Doctrine of
Equivalents?, 20 ST. Louis U. PUB. L. REV. 281, 282-83 (2001).
178. See, e.g., Mark L. Hayman & Lisa E. Stahl, Homology Claims Face New Equivalents
Hurdles; Variations on DNA and Protein Molecules May Be Harder to Protect, 26 NAT'L L.J. S4
(2003) (discussing the impact of the Supreme Court's narrowing of doctrine of equivalents claims
on biological molecule patents due to the existence of many functional homologs of patented
proteins).
179. Id.
180. Id. 'The actual effect on activity of a given alteration in amino acid sequence can be
unpredictable," resulting in frequent rejection of homolog claims by the USPTO for claims that
could not be replicated without undue experimentation. Id. This leads frequently to amended
claims with respect to homology. Id.
181. Id.
182. Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushki Co., Ltd., 535 U.S. 722 (2002);
Hayman & Stahl, supra note 178, at S4.
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patent.18 3 The total effect of the Supreme Court's interpretations is
unclear as cases on the issue have been remanded for further trial
court proceedings.18 4 Uncertainty as to the potential value of the
multitude of protein patents currently being filed or in effect
presumably will lead to greater protective efforts by private industry
to recoup profits.18
On the opposite end of the spectrum are judicial and USPTO
decisions that uphold broadly drafted patents. For example, the
Federal Circuit upheld a number of patents for the protein
erythropoietin ("EPO") which were produced through recombinant
DNA technology.18 6 The patents' claims were broadly drafted as
covering any EPO protein that was "vertebrate," "mammalian," and
"non-naturally occurring." 18 7  The court has enforced the patents to
cover any use of mammalian cells for the production of EPO, which
effectively gives the patent owner complete control over the production
and distribution of this valuable protein, since all potential variations
would likely fall within the claims.188
Another example is DuPont's patent on its genetically altered
"OncoMouse," which the company exclusively licenses.18 9 The patent
potentially covers inserting any oncogene into any mammalian
species.1 90 Transgenic mice patents such as this have had some
chilling effect on scientific research. 19' The acceptance of broadly
reaching patents such as these encourages broadly drafted patents on
all fronts.1 92
183. Wharton, supra note 177, at 290.
184. Hayman & Stahl, supra note 178, at S4.
185. See e.g., Molecules v. Information, supra note 3, at 204-05, 212 (describing one
company's efforts to maximize profits by patenting every discovery possible, using roadblocks
and trading rights to proteins because of the uncertainty of the market).
186. See, e.g., Amgen, Inc. v. Hoechst Marion Roussel, 314 F.3d 1313, 1324-25 (Fed. Cir.
2003).
187. Id. at 1324-25.
188. Cyranoski, supra note 8, at 11.
189. Richard Stallman, Are U.S. Patents Too Broad?, SCIENCE., July 19, 2002, at 336.
190. Id. An "oncogene" is a "gene thought to be capable of producing cancer." BIOTECanada,
Biotech Classroom-What is Biotechnology?-Glossary, at http://www.biotech.ca/EN/glossary.
html.
191. John P. Walsh et. al, Working Through the Patent Problem, SCIENCE, Feb. 14, 2003, at
1021.
192. For example, patent 6,647,341, issued in November 2003, covers the use of an algorithm
to distinguish samples in a gene expression array, and is broadly drafted such that it may cover
"pretty much any application of gene-expression arrays for clinical data."' Jocelyn Kaiser, Patent
Sprawl: From Genes to Gene Interpretation, SCIENCE, Dec. 12, 2003, at 1878. The NIH is so
concerned about this issue that it recently has awarded a $1.2 million grant to determine the
consequences of judicially accepted broad patents covering biological molecules. Cyranoski,
supra note 8, at 11.
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5. The Experimental Use Exception-No Longer a Safe Haven for
Academic Research
Finally, and perhaps most importantly in terms of the free
exchange and use of research information, is judicial re-interpretation
of the experimental use exception. The experimental use exception is
a narrowly construed doctrine that "protects alleged infringers who
use patented inventions solely for experimental purposes, such as
testing whether a device functions as claimed or re-creating a process
to observe its effects from a scientific perspective." 193 Many, if not
most, academic researchers believe that this exception covers all
academic research, so they have no reason to worry about broad
reaching industry patents. 194
In Madey v. Duke University, 95 however, the Federal Circuit
made it clear that the experimental use doctrine does not exempt
academic researchers from patent infringement.1 96 The argument
centered on the potentially infringing use of laser technology that
Madey had developed and patented at Duke University.1 97  The
district court granted summary judgment in favor of Duke, believing
the experimental use exception applied to institutions using patents
with no commercial purpose. 98 The Federal Circuit reversed, stating
that the exception only encompasses use for "amusement, to satisfy
idle curiosity, or for strictly philosophical inquiry." 199
The court stated that the University may be using the patented
technology for research that would result in direct commercial gain
from its own patentable inventions. 200 Further, even if the uses were
not for direct commercial gain, the court concluded that if the
experimentation was to "further the institution's legitimate business
objectives," it would not be subject to the exception. 20 1 Under this
interpretation, any educational research that utilizes patented
193. Tom Saunders, Renting Space on the Shoulders of Giants: Madey and the Future of the
Experimental Use Doctrine, 113 YALE L.J. 261, 261 (2003).
194. Cyranoski, supra note 8. at 11.
195. 307 F.3d 1351 (Fed. Cir. 2002), cert. denied, 123 S. Ct. 2639 (2003).
196. See id. at 1360-63 ('The correct focus should not be on the non-profit status of Duke but
on the legitimate business Duke is involved in.").
197. Id. at 1352-53.
198. Id. at 1354-55. Madey also successfully argued that the District Court in effect shifted
the burden of proof to the patent holder to prove that the use was not experimental, an argument
that the Federal Circuit rejected. Id. at 1360-61.
199. Id. at 1362. The use does not qualify when "it is undertaken in the 'guise of scientific
inquiry' but has 'definite, cognizable, and not insubstantial commercial purposes.'" Id. (quoting
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material is potentially infringing if unauthorized by the patent's
owner.20 2 University research is conducted to aid in education, to
maintain or to obtain status as a quality research facility and to
obtain funding through grant programs. 20 3 All of the above reasons
are more than enough to bring public research out of the experimental
exemption.
It is unclear what impact the Madey decision will have on
future academic research. Madey was undoubtedly a "unique"
decision involving a disgruntled former employee suing to restrict the
use of patents he developed while working at the University.204
Private industry has, on a whole, been very tolerant of infringing uses
by research institutions, since additional research can potentially
increase the value of their patents and lawsuits can cause more
damage than they are worth.20 5  However, private industry is
business, and where value is being threatened, such as infringing use
of diagnostic tests in clinical research, companies may be more willing
to litigate. 20 6 The proteomics field is a very high risk investment
because of the uncertainty and large front-end cost in uncovering
major profit-producing proteins, such as drug targets. 20 7 Thus, the
economic nature of the industry may also lend this field to an
increased willingness to litigate. 208
202. See, e.g., Saunders supra note 193, at 263 (arguing that the decision effectively
destroyed any use of the exception).
203.
Major research universities, such as Duke, often sanction and fund research projects
with arguably no commercial application whatsoever. However, these projects
unmistakably further the institution's legitimate business objectives, including
educating and enlightening students and faculty participating in these projects. These
projects also serve, for example, to increase the status of the institution and lure
lucrative research grants, students and faculty.
Id.; see also Cyranoski, supra note 8, at 11 (noting that "the university was using the technology
in the business of teaching and getting grants, not to satisfy idle curiosity").
204. Madey, 307 F.3d at 1352-53. Madey was removed as the head of Duke's reputable free
electron laser laboratory after disagreements with the institution and resigned his position the
next year. Id.
205. See Walsh et al., supra note 191, at 1021 (reporting survey results indicating that
intellectual property holders "tolerat[e] academic research infring[ment] ... because it can
increase the value of the patented technology"; additionally, "the small prospective gains from a
lawsuit [a]re not worth the legal fees, the risk of the patent being narrowed or invalidated, and
the bad publicity from suing a university").
206. See id. (noting that the tolerance of academic infringement does not extend to patents
on diagnostic tests used in clinical research).
207. See Service, supra note 3, at 2083 (noting that the interaction between competing




IV. TRADITIONAL PATENT LAW MAY NOT ADEQUATELY OR EFFICIENTLY
COVER THE NATURE AND ECONOMICS OF PROTEOMICS
There are several benefits and drawbacks to the current
aggressive market in biotechnology patents, in particular proteomics.
The economic market in which private industry operates is in direct
conflict with the public sector and will continue to cause uncertainty
and tension as long as current patent law is in play.20 9 Several
biotechnology-specific alterations have been proposed, but they may
not adequately address the potential problems and the resulting
potential backlog of litigation proteomics may engender as it comes to
fruition in the next few decades.
A. Private Industry, Research and Development, and Incentives to
Innovate
The private biotechnology industry as a whole has highly
supported the broad patenting of biological methods and molecules. 210
A key element of the patent theory is to provide protection for
innovation as an incentive to promote more innovation. 211  This
incentive is particularly important in biotechnology, where outcome
uncertainty provides for exceptionally risky investments and start-up
capital for new research and development reach staggering
amounts. 212 Biotechnology companies argue that limiting or altering
the patent law with respect to biological molecules will be a strong
disincentive for investment and invention.21 3
209. See supra Part III.B.5. (discussing the evolution of the experimental use exception).
210. See e.g., Laurie L. Hill, The Race to Patent the Genome: Free Riders, Hold Ups, and the
Future of Medical Breakthroughs, 11 TEX. INTELL. PROP. L.J. 221, 239-40 (2003). For example,
the Biotechnology Industry Organization has been a strong lobbyist for traditional patent
protection of biotechnology in Congress. Id. at 240-41.
211. This theorv is embodied in the Constitution. See U.S. CONST. art. I. 4 8. cl. 8 ("To
vromote the Progress of Science and useful Arts. bv securing for limited Times to
Authors and Inventors the exclusive Right to their respective Writings and
Discoveries.").
212. See Hill, supra note 210, at 239-40 ("Biotechnology industrialists forcefully maintain
that strong patent protection is essential to protect risky investments in biology-based research
because of the unusually high failure rate of products.")
213. The argument can be persuasive. The U.S. currently has over 1,400 biotechnology
companies, with revenues over $20 billion annually and over 9,000 patents granted per year. Id.
at 236-37. The industry has also tripled in size since 1992. Id. The relaxation of certain aspects
of the patent law has appeared to have spurred at least part of this growth. Id.
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1. Potential Benefits of Strong Patent Protection to Biotechnology
Supporters of current or more relaxed standards of
patentability disparage arguments that biotechnology should have its
own specific set of laws, and dismiss most of the public sector's fears
as purely theoretical and highly improbable. 214 These entities pose
several arguments in favor of maintaining the status quo. Drawing
examples from other rapidly advancing industries, such as
informational technology, biotech companies say that genes and
proteins are not so different from any other inventions that have
successfully developed under the current Patent Act.215 They further
argue that lack of patent protection may completely remove any value
in the research, since much time, effort and money has to be expended
in the front-end to reap any further value that free riders could easily
take and exploit. 216 In fact, some supporters claim that more patent
protection may be necessary in this area because of the many
techniques available to defeat or work around patents. 217 Private
patent holders rarely enforce patents against academic institutions for
non-commercial uses.21 8 If private industry resorts to this type of
patent enforcement, supporters of the current system argue that the
use of cross-licensing will alleviate most of the conflicts between the
sectors. 219
2. Counterarguments
Conventional patent theory completely supports a strong
protection regime for fields that need incentives for private research
and development. 220 However, biotechnology is unlike most other
214. Id. at 240.
215. See id. ("According to those in biotechnology, gene patents represent real invention and,
therefore, should be treated as any other technology within the current patent system.").
216. See, e.g., Arti K. Rai & Rebecca S. Eisenberg, The Public Domain: Bayh-Dole Reform
and the Progress of Biomedicine, 66 LAW & CONTEMP. PROB. 289, 295 (2003) ("[W]ithout patents
to permit pricing in excess of marginal cost, no one would be motivated to incur R&D expenses
that were vulnerable to appropriation by free riders").
217. For some specific examples, see infra Part IV.B.
218. See, e.g., Rai & Eisenberg, supra note 216, at 296 ("Some commentators have also
argued that patents rarely impose high costs on academic research because patent holders
practice an informal regime of price discrimination in favor of nonprofit researchers, primarily by
not enforcing their patents against such researchers for non-commercial uses.").
219. The biotechnology industry has argued that the current product licensing system that
occurs between companies and with university researchers creates an ideal partnership which
acts to increase "improvements in medical diagnosis and treatment." Hill, supra note 210, at
240-41.
220. See id. at 238-41 (discussing economic theories supporting biotechnology patents).
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technology and defies many comparisons. Arguments that the proper
incentives will not exist without strong patent protection are
diminished by the fact that a great number of the biotechnology
discoveries result from direct or indirect public funding.221  Basic
scientific research has continued to progress at an increasing pace
without the promise of profit or the assumption that downstream
protection of inventions exists.222 Public resources, often in very large
amounts, are frequently expended by many different sources in order
to answer specific limited issues.223  For example, when using
proteomics research to discover the cause and potential cure for a
disease, researchers may look to abnormalities in genetic coding for a
particular protein, examine protein expression through comparisons
between diseased and normal tissue, or use computer modeling to
predict where abnormal proteins will occur.224  Approaching the
problem from multiple directions allows many different researchers to
work on solving similar issues and provides reinforcement for
discoveries. 225
Further, as stated previously,226  the narrowing of the
experimental use exception has left academic institutions that use
patented technology or molecules at the mercy of the patent holders.
Protein patents have the potential to protect not only the molecule and
its functionality, but the information it contains. 227 Therefore, in the
case of proteomics, a company may claim many thousands of proteins
and all the information they contain. 228 In addition, broad claim
221. For example, 71.6% of the scientific references cited by biotechnology patents are
derived from publicly funded basic science research. Id. at 242.
222. Id. at 242-43. The driving force in basic science is publication and peer acceptance.
Public recognition for making a large contribution towards his or her field of study, obtaining
grant funding, and disclosing their discoveries to other members of the scientific community
make the opportunity for patent protection much less important to most biology researchers. Id.
Obtaining a patent, while always attractive from a financial security standpoint, remains a
secondary goal.
223. See id. at 243-45 (discussing "the norm[s] in scientific progress").
224. See, e.g., National Cancer Institute, Questions and Answers: OvaCheck, at http://www.
cancer.gov/newscenter/pressreleases/ProteomicsOvarian (last visited Oct. 15, 2005) (discussing
proteomic methods used to aid in detecting ovarian cancer at earlier stages); see also Adler,
supra note 104, at 1 (discussing patent strategies of certain firms).
225. See Hill, supra note 210, at 243-44 ("[Wlithin the scientific community, the validation
and extension of a scientific finding by other researchers is essential in searching for the
'scientific truth' among various research models and approaches.").
226. See supra Part III.B.5 (discussing the current status of the experimental use exception).
227. See, e.g., Stolpa, supra note 137, at 362-63 (criticizing one court's decision to focus on
"technical possession and description, neither of which is an accurate description of the
invention's scope").
228. See, e.g., Cyranoski supra note 8, at 11 (describing fears that companies will "attempt to
claim ownership of any approach to knocking out" proteins).
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interpretation, causing protection of downstream molecules or
methods, gives a potentially unbreakable monopoly and would allow
the holder to elevate unreasonably the cost of licensing crucial
elements of research. 229
By inhibiting or threatening future innovations, increased
biotechnology patent protection has "the exact opposite" effect
intended by the policies behind a strong patent system.230 Since
current patent laws benefit the few institutions with the power to
mass patent molecules, very little cooperation in cross-licensing may
be necessary. 231 Even if companies are willing to offer reasonable
licensing fees for their products, uncertainty in the system and the
law, "imperfect information, disparate assessments of value, and the
danger that pioneer patent holders will simply misappropriate the
confidential research plans of follow-on researchers" may cause
prohibitive transaction costs in license negotiations.232
B. The Public Sector, Open Research, and the Future of Scientific
Knowledge
As made clear in the previous sections, academics and other
publicly funded researchers in placed in a precarious position under
current law. The incentives provided under the current patent system
are shifting scientific emphasis from the open exchange of knowledge
to guarded information doled out only if profitable. 233  Public
databases of knowledge still exist for biomolecules and may be
adequate for some research, but public databases pale in comparison
to the periodically-updated and intensively researched databases from
229. See Rai & Eisenberg, supra note 216, at 295-303 (discussing proprietary barriers to
biomedical research and development). "Reach-through" rights, by which companies attempt to
license downstream products if patent coverage of the gene or protein molecule fails, is the
subject of great contention in the scientific community. See, e.g., Hill, supra note 210, at 244-45
("[N]egotiating patent licenses and valuing the risk of reach-through royalty or invention right
agreements result in high transaction costs for basic science research and will quickly interfere
with the norms of research.").
230. See, e.g., Cyranoski, supra note 8, at 10 (noting that the fear surrounding some of the
early gene patents was that their potentially huge reach would provide "a major disincentive to
investment in research and development - the exact opposite of what the patent system is
supposed to achieve"). Hill argues that, by threatening academic research, strong patent
protection acts to reduce the disclosure of information in the public sector from fear of discoveries
being improved upon and then patented by those with greater resources. Hill, supra note 210, at
244.
231. Larger firms may work out agreements among each other or continue the pattern of
merger, thus eliminating their need to cross-license with smaller firms or universities.
232. Rai & Eisenberg, supra note 216, at 297.
233. C.f. Proper Scope, supra note 110, at 242 (describing the shift from "open science" to
increasing corporate influence on basic research).
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the private sector.234  University and other publicly-funded
researchers are, of course, able to and encouraged to patent the
discoveries they make that qualify under the current system. 235 In the
fast-paced world of protein patenting, however, strength lies with the
resources, workers, and capital of private industry.
Nevertheless, there remain some avenues to engage in
proteomic research for those who do not hold patents in proteins. The
Supreme Court's interpretation of the doctrine of equivalents based on
amended claims 236 may allow the use of homologous proteins with
similar function. 237 Further, the USPTO's increased utility standards,
to the extent they are good law, allow competing researchers more
time to uncover "specific, substantial and credible" uses for proteins
before they are claimed. 238 Biotechnological methods and processes, as
well as bioinformatics databases, share many features with other
machine and software patents, thus enabling creative competitors
leeway to design around their claims.239
As a whole, however, the current patent law encourages the
patent races occurring in the proteomics field, leaving those with the
most resources obtaining the most territory and the most downstream
control of the industry. Without special considerations for proteomics
(and probably genomics as well) that fine tune the particular problems
234. See Pachnanda, supra note 115, at 230-46 (arguing for sui generis reform legislation for
databases in the United States similar to that adopted by the European Union). The decrease in
government funding over the past few years has further promoted aggressive tactics from the
private sector to capture the important bioinformatics market. Id. at 237. "[S]everal non-profit
biotech databases have been forced to shut-down." Id. at 234.
235. The Bayh-Dole Act of 1980 was enacted to increase the number of patents resulting
from government-sponsored biotechnology research, and has been very successful at increasing
university presence in the patent race. See, e.g., Consumer Project on Technology, Health Care
and Intellectual Property (providing information and internet links regarding the Bayh-Dole
Act), at http://www.cptech.org/ip/health/bd/ (last visited Feb. 23, 2005); 35 U.S.C. §§ 200-212
(2005).
236. See supra Part III.B.4 (discussing judicial interpretations that have led to patent
uncertainty).
237. See Hayman & Stahl, supra note 178, at S4 (analyzing recent federal case law
interpreting the doctrine of equivalents). Of course, the response to the threat of lost profits
from inadequate patents is to re-double their efforts to find, isolate and patent any similar
proteins as well. See Service, supra note 3, at 2083 (noting that two of the major players in this
industry have collectively filed more than 25,000 DNA-based patent applications).
238. See supra Part III.B.3 (contrasting the USPTO's utility standards with those applied by
federal courts).
239. Broadly interpreted machine and process claims in biotechnology patents, however,
have the potential to disrupt research in the field as much as broad patents in biomolecules such
as proteins. See Kaiser, supra note 192, at 1878 (quoting one researcher who described the trend
towards patenting biomedical research tools as "destructive for science"). As there are much
stronger arguments for these types of patents to remain a part of the traditional patent system,
further discussion on this point is beyond the scope of this Note.
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presented, the future direction of scientific research and the allocation
of scientific resources may rest in the hands of a select few. In a field
where publicly funded research has played such a critical role in
development and discovery, this at least is cause for concern and
study. 240
C. Other Considerations
Beyond the issue of whether biological informational molecules
should be patented at all, there are several other factors in proteomics
and genomics which will likely generate much future litigation. For
example, there are thousands of gene and protein patent applications
applied for and accepted every year by the USPTO, all with multiple
potential functions.241 It is highly likely that situations will arise
where a gene patent owner will not hold the patent for the protein the
gene encodes. 242  Assuming the particular function has enough
potential value, such as in the pharmaceutical field, both parties are
sure to litigate who has control over the uses for the proteins.243
Again, the broadness of patent claims and the length of the reach of
gene patents are very important issues in the proteomics industry.
To summarize, patenting the products of the proteomics
industry raises many distinct problems and conflicts. Considerable
front-end expense may be necessary to reap any future rewards, so
some degree of intellectual property protection is required to
encourage investment by private industry.244 Patent protection of
240. Doomsday scenarios aside, in the absence of new regulations the ability to control mass
amounts of intellectual property territory in this field will enable the relatively few biotechnology
companies to operate with the public sector on essentially their own terms.
241. See, e.g., Service, supra note 3, at 2082-83 (noting that two of the major players in this
industry have collectively filed more than 25,000 DNA-based patent applications).
242. See id. (positing that because of the great uncertainty as to the interaction of gene and
protein patents, "showdowns may be inevitable").
243. Considerable research and development money would have been invested in both the
gene patent and the protein patent. For the owner to recoup any real value from their efforts,
they would have to be able to claim control over the functional aspects of the protein or protein-
products. Therefore, at the very least, negotiation will have to occur to determine whose patent,
the gene owner or the protein owner, will cover the end uses. See id. (predicting that "people will
work out a deal" to cross-license each other's patents in order to resolve these gene versus
protein patent disputes). Considering the stakes involved and the substantial amount of
uncertainty that remains in this area of the law, however, these disputes will likely be litigated
frequently. Id.
244. Several treatises have discussed the possible benefits of other types of intellectual
property protection for biomolecules, such as copyright and trade secret protection, and have
concluded that these sources are very inadequate. See, e.g., DUCOR, supra note 36, at 139-41
(discussing the reasons the U.S. Copyright Office "seems currently to exclude the
copyrightability of genetic sequences and proteins" and arguing that trade secret law "does not
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proteins may inhibit downstream innovation by giving too much
control over end-products to the patentee, however, given the
judiciary's relaxation of the written description and utility
requirements. 245 Uncertain interpretation of the scope of claims and
inconsistency in guidelines by the USPTO and Federal Circuit is not
enough to impede investment where there are resources and potential
reward, but they may lead to increased future litigation.246 Further,
current patent interpretation threatens to alter the traditional
function of scientific research if patent holders strictly enforce their
rights against academically or publicly funded researchers. 247
V. UNIQUE LEGAL PROTECTION FOR BIOLOGICAL MOLECULES-THE
BEST ALTERNATIVE TO REESTABLISHING BALANCE WITHIN THE
BIOTECHNOLOGICAL SCIENCES
Scholars have suggested many distinct alterations that could
be made to the existing patent system to improve the Patent Act with
respect to biotechnology; many of these ideas remain viable
alternatives. 248  Separate legislation designed to protect biological
molecules may be the best alternative, however, for several reasons.
First, significant alterations made by the USPTO specifically
for biological molecules may meet resistance from the Federal Circuit
and possibly the Supreme Court, since the 1952 Patent Act, its
revisions and the courts' relaxed precedents are binding.249 Recent
history has shown a general movement away from restrictions on
patentability that would more reasonably control the problems raised
provide enough protection"); McBride, supra note 23, at 1345-56 (explaining the shortcomings of
both copyright and trade secret protection as applied to biomolecule discoveries).
245. This phenomenon is partly due to the uniqueness of biomolecules as having both
functional and informational aspects.
246. This uncertainty may ultimately be a deterrent to those who do not have the resources
to compete with those established in the field.
247. See supra Part III.B.5 (discussing the judicial re-interpretation of the experimental use
exception).
248. See Hill, supra note 210, at 246-58 (suggesting shorter and possibly renewable patent
terms, fair use exceptions, stringent licensing control, stricter limitations on the boundary of a
gene patent or some combination of these ideas as possible improvements); Sung, supra note 1,
at 268 & n.17 (recognizing an expanded infringement exemption for pure academic or otherwise
non-commercial research similar to the fair use defense under copyright law, a broader
infringement exemption for experimental use, and compulsory licensing as attractive
alternatives). Others have suggested scaling back the heightened utility and written description
requirements to bring biotechnology back "into the fold" of current patent law. See Esoy, supra
note 75, at 163-64 (proposing less stringent utility requirements); Stolpa, supra note 137, at 361-
66 (arguing that the heightened written description requirement should be pruned back).
249. The Federal Circuit has stated that the USPTO's guidelines do not bind the court when
interpreting patent law. See supra text accompanying note 174.
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by patenting biological molecules. 250 A stronger patent system may be
necessary to encourage technology that has less interest or less
potential to produce great returns on investment. 251 Proteomics has
sufficient interest and support from both private and public
investment, however, especially due to the medical advancements that
the field promises. 252  Therefore, the innovations produced by
proteomics would very likely continue to occur under a more restricted
and specifically tailored system.
Second, proteomics is a burgeoning field that is developing
rapidly but with much uncertainty and risk; this has resulted in the
"land grab" of protein territory. 253 The court system is restrained in
its ability to reform the patent system by the cases it receives. Since
the greatest value of the biological molecule patents being currently
issued likely will not be fully realized for several years,254 issues
raised in litigation will likely not be addressed before much of the
available territory is claimed by private industry. By the time the
courts take decisive action to correct the existing imbalances, the
damage may by too severe to remedy 255 In other words, proteomics
technology may so far out-pace adaptation of the Patent Act that a
separate system set up earlier would better balance competing policies
and would better adapt to such rapid changes.
Third, the existing system of patent law may never be able to
appreciate fully the dual nature of biological molecules and the
potentially devastating monopolies these patents create. 256  Even
assuming that the judiciary will approve of any reformatory actions by
250. See supra Part III.B.
251. See supra Part IV.A.
252. See e.g., Jonathon M. Barnett, Cultivating the Genetic Commons: Imperfect Patent
Protection and the Network Model of Innovation, 37 SAN DIEGO L. REV. 987, 990-94 (2000)
(arguing that the normal theories for patent protection do not explain the pharmaceutical
industries' investment in uncertain biotechnology).
253. See Service, supra note 1, at 2074 (explaining why proteomics has become a field in
which both "money and hype are flowing fast and furious").
254. See Molecules v. Information, supra note 3, at 205-06 (noting that the holders of such
patents are essentially making long-term bets that their patents will be used in the development
of highly profitable drugs at some point in the future).
255. See, e.g., Hill, supra note 210, at 246:
It is true that the Federal Circuit will likely craft a more workable framework that
fully appreciates and balances the unique nature of genes and the contributions of the
inventors and basic science researchers. However, the question is whether there is
time to wait for the courts to resolve the ongoing debate as more gene patents issue
and basic science research grapples with increasing tolls on their research.
See also Sung, supra note 1, at 270 ("[T]he development of the legal authority trails years, if not
decades, behind").
256. See, e.g., Stolpa, supra note 137, at 362-63 (criticizing the Federal Circuit Court's
myopic analysis of the written description requirement with respect to biological molecules).
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the USPTO and will distinguish precedent to control the scope of these
patents, the policies of Chakrabarty and the statutory requirements
for patentability were not equipped to handle the power a person who
holds a patent in a biological molecule may possess. 257 Thus, for
proteomics and other biotechnology, the current system may
unnecessarily inhibit innovation as compared to another system that
properly recognizes that control of the underlying information in a
biological molecule may, in theory, prevent any further use without
approval of the patent owner.
Finally, Congress, with its political accountability and ability
to respond relatively quickly to crucial issues, is best suited for
ensuring that proper incentives are maintained in the industry. 258
The Patent Act as a whole seems to work properly for the innovations
for which it was designed. 259 A complete overhaul of the Patent Act
therefore seems unnecessary for most patented technology, but would
likely have to occur to address the biotechnology issues raised in this
Note. Sui generis legislation would be able to address all foreseeable
aspects of biological molecule patents while leaving the existing patent
system more or less intact.
Examples illustrate that some fields are better protected by
legislation other than the Patent Act. These include the plant
patenting acts, the Semiconductor Chip Protection Act ("SCPA") and
the Orphan Drug Act ("ODA"). 260  Congress designed the plant
patenting acts to address specific aspects of non-patentability with
respect to modified plant species, but these modifications are now
considered, with the relaxation of patent requirements, to be
separately patentable under the Patent Act.261 Similarly, the SCPA
was enacted in 1984 to grant limited protection to chip designs since
they were not considered patentable or copyrightable. 262 Congress
257. See, e.g., Molecules v. Information, supra note 3, at 196 (asserting that the fundamental
problem with the current jurisprudence is that it continues to view DNA sequences as molecules,
and not information, when these sequences clearly share characteristics of both).
258. Of course, accountability also subjects congressional reform to greater influence by
special interests groups, thus making it more likely that the direction of proteomics legislation
will be shaped primarily by the pharmaceutical companies, which have the most to gain and to
lose from any patent law alterations.
259. Examples include mechanical and engineering innovations.
260. Semiconductor Chip Protection Act, 17 U.S.C. §§ 901-914 (2005); Orphan Drug Act, 21
U.S.C. § 360aa-ee (2005). The Plant Protection Act and Plant Variety Protection Act are
discussed briefly supra in Part H.A.
261. See Ducor, supra note 36, at 144-45 (explaining that the Plant Patenting Act and the
Plant Variety Protection Act "are examples of intellectual property rights created because plant
varieties doubtfully met the requirements of section 101 (patentable subject matter), 103 (non
obviousness), and 112 (description, reproductibility) of the Patent Act").
262. Id. at 148-49.
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enacted the ODA to encourage development of drugs for rare diseases,
where the risks of investing may significantly outweigh the potential
rewards in production. 263 That Act, however, also addresses specific
issues in drug manufacturing that have caused problems and conflicts
in the industry, thus demonstrating a correlation to proposed
proteomics-specific legislation. 264
Congress enacted the above measures to grant protection to
otherwise unprotected inventions or to provide incentives for
innovation. 265 Separate legislation for proteomic patents, however,
would ideally provide different and well-defined, not necessarily less,
protection for protein products while maintaining the proper
incentives for innovation. 266 The goal of any new legislation that
would specially protect proteomics and biological molecules would be
to ensure that no one group will be able to assume too much broad-
reaching control of all research aspects by limiting the downstream
reaches of protein innovations or reach-through licenses. Any
legislation should still provide incentives to non-publicly funded
entities to invest in further research and development through limited
protection of their discoveries. Moreover, legislation that specifically
addresses the issues raised by proteomics, such as the dualistic
informational and functional aspects or the importance of traditional
scientific research in this field, will only add clarity and promote
compromises which will further encourage investment and innovation.
VI. CONCLUSION
Every legal system has the capacity for improvement, and the
Patent Act has been adapted over two centuries to incorporate many
diverse fields and issues. The courts have been very adept at
interpreting and re-interpreting statutory language to accommodate
emerging technologies, such as the shift towards an information-based
economy; and, for the most part, the "useful arts" have adapted well in
263. Id. at 145.
264. Id. at 145-48.
265. Id. at 149.
266. Ideally, the legislation would be preceded by intensive scientific and business study
partnerships that could share and balance concerns from both the private and the academic
sectors to craft working legislation. The importance of proteomics to future medical and other
scientific breakthroughs makes the issue much more salient to the public at large, if given the
opportunity, in comparison to other intellectual property expansions (such as copyright and
trademark law). Patent protection in biological material also brings forth ethical issues and has
met with some opposition from religious organizations and the public at large. See, e.g.,
Molecules v. Information, supra note 3, at 208-09 (discussing some of the concerns that have been




response to the changing requirements. An existing system can only
be stretched so far, however, without a complete overhaul. Science is
constantly pushing boundaries farther than the previous generation
imagined that it could. Proteomics represents the latest boundary and
one that will dominate the biotechnological landscape for decades to
come. In order to accommodate this revolutionary system, as well as
to anticipate the further merger of biology and the technological arts,
something beyond tinkering with the existing system may be
necessary. Sui generis protection represents the best scenario for
encompassing this constantly expanding science and for providing a
check to the potential volumes of litigation this area will surely
engender.
J. Jason Williams*




"Resolvability": A New Approach to
Regulating Class Actions
Allan Erbsen 58 Vand. L. Rev. 995 (2005)
This Article develops normative and doctrinal innovations to
cope with a pivotal yet undertheorized question in most proposed
class actions: assuming that a class has adequate representatives,
how much variance among class members' circumstances should
courts tolerate? Class actions seeking monetary damages would be
much less controversial if the factual circumstances of every class
member were exactly alike. In an imagined world of perfect
homogeneity, shifting from an individualized to an aggregative
mode of adjudication would promote efficiency, mitigate collective
action problems, and counterbalance defendants' inherent
economies-of-scale without sacrificing accuracy or redistributing
entitlements among class members. In the real world, however, most
classes encompass at least partially heterogeneous claims spread
across a spectrum of merit and economic value. This diversity
creates opportunities for strategic behavior that can distort the
outcome of trials or of settlements negotiated in the shadow of trial.
The Article defines and explores three phenomena that create such
distortions: "cherry-picking," "claim fusion," and "ad-hoc
lawmaking. "
The potentially mischievous consequences of heterogeneity in
class actions suggest that courts should have a normative theory and
doctrinal mechanism to distinguish between acceptable and
excessive diversity among proposed class members. The Article
addresses the normative question by introducing and justifying
three principles to structure certification criteria: "finality,"
"fidelity," and "feasibility." The Article then applies these principles
to assess the forty-year-old "predominance" standard that currently
governs how courts decide whether to certify diverse damages
classes. This analysis reveals that the predominance standard is
conceptually incoherent and that widely-cited doctrine applying it is
normatively unsound.
To fill the gatekeeping function that the predominance
standard ineffectively attempts, the Article proposes a new
"resolvability" test for courts to apply when deciding if a class action
would be an appropriate procedural vehicle for adjudicating diverse
claims and defenses. The proposed test would permit certification of
class actions seeking money damages only when: "The court has a
feasible plan to answer all disputed questions of law and fact that
must be resolved before entering judgment for or against class
members under the law governing each class member's claim and
applicable defenses." The Article then discusses broader
implications of its proposal that highlight a dynamic relationship
between substantive and procedural constraints on regulation of
mass risks.
